๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Frankfurt am Main
Clinical trial register · Germany

Clinical Trials in Frankfurt am Main, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 45 Essen 30 Hamburg 30 Leipzig 22 Dresden 22
Narrow the registerReset
Recruitment status
Phase
Site location
Berlin45 Essen30 Hamburg30 Leipzig22 Dresden22
All 110 locations
Target enrolment
to

Trials with a site in Frankfurt am Main

12 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
NCT07612267Lactation, Inflammatory Bowel Disease
Eli Lilly and Company
Phase 4
14
Frankfurt am Main, Potsdam
2026-08-05
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
Eli Lilly and Company
Phase 1
460
Berlin, Cologne, Essen, Frankfurt am Main
2026-04-17
Recruiting
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
NCT06598943Ulcerative Colitis, Ulcerative Colitis Chronic
Eli Lilly and Company
Phase 2
143
Augsburg, Berlin, Brandenburg an der Havel, Duisburg, Frankfurt am Main, Halle, Hamburg, Hanover
2024-10-10
Recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
Eli Lilly and Company
Phase 1
340
Berlin, Essen, Frankfurt am Main
2024-09-19
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Eli Lilly and Company
Phase 3
510
Berlin, Dresden, Frankfurt am Main, Jena, Lรผbeck, Sachsen
2024-04-29
Active, closed
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008Perennial Allergic Rhinitis (PAR)
Eli Lilly and Company
Phase 3
450
Berlin, Dresden, Frankfurt am Main, Heidelberg, Marburg, Weisbaden
2024-04-26
By invitation
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05735483Atopic Dermatitis, Eczema
Eli Lilly and Company
Phase 3
333
Darmstadt, Frankfurt am Main, Bad Bentheim, Mรผnster, Dresden
2023-03-09
Recruiting
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases
Eli Lilly and Company
Phase 3
595
Bad Bentheim, Berlin, Dresden, Frankfurt am Main, Hamburg, Mainz, Mรผnchen, Mรผnster
2023-02-27
Active, closed
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
NCT05433584Type 2 Diabetes
Eli Lilly and Company
Phase 4
780
Frankfurt am Main, Bochum, Essen, Saint Ingbert, Pirna, Oldenburg in Holstein, Bad Mergentheim, Gelnhausen
2022-08-01
Active, closed
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
Eli Lilly and Company
Phase 3
925
Freiburg im Breisgau, Heidelberg, Nรผrtingen, Ulm, Tรผbingen, Munich, Frankfurt am Main, Duisburg
2022-04-14
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
874
Ludwigsburg, Donauwรถrth, Erlangen, Mรผnchen, Frankfurt am Main, Hanover, Essen, Mรถnchengladbach
2021-10-04
Active, closed
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
NCT04232553Crohn's Disease
Eli Lilly and Company
Phase 3
996
Pforzheim, Wรผrzburg, Frankfurt am Main, Lauterbach, Hanover, Bottrop, Wipperfรผrth, Leipzig
2020-06-22
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/frankfurt-am-main

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 12 of those studies with a site in Frankfurt am Main that also match the filters currently applied.

How many clinical trials are recruiting in Frankfurt am Main?

6 of the 12 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 0 have not yet opened recruitment, 5 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Frankfurt am Main), 12 studies
PhaseStudiesRecruitingShare
Phase 37258.3%
Phase 12216.7%
Phase 42116.7%
Phase 2118.3%

Most active sponsors

Lead sponsors with the most studies (Frankfurt am Main)
Lead sponsorStudiesRecruiting
Eli Lilly and Company126
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.